{"entity":{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","aka":["LaNova Medicines Limited"],"tldr":"LaNova Medicines is a Shanghai biotechnology company, wholly owned by Sino Biopharmaceutical since July 2025, running 10 late-stage cancer trials of LM-168, LM-108 and LM-299 in gastric & gastro-oesophageal junction cancer.","summary":"LaNova Medicines, based in Shanghai, China, is a biotechnology company. In July 2025 Sino Biopharmaceutical bought the 95.09 per cent of LaNova it did not already own, for a total consideration of about USD 951 million, making it an indirect wholly owned subsidiary; LaNova had earlier licensed its PD-1 and VEGF bispecific antibody LM-299 to MSD and its GPRC5D antibody-drug conjugate LM-305 to AstraZeneca. LaNova Medicines is a clinical-stage biopharmaceutical company developing monoclonal antibodies, antibody-drug conjugates and bispecific antibodies for tumour immunology and the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 10 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LM-168, LM-108, LM-299, LM101 and LM-350 in gastric & gastro-oesophageal junction cancer. The largest, NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), plans to enrol 400 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.lanovamedicines.com"},{"label":"HKEX: Sino Biopharmaceutical discloseable transaction, full acquisition of LaNova (15 July 2025)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0715/2025071500770.pdf"},{"label":"HKEX: Sino Biopharmaceutical 2025 annual report","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042901036.pdf"},{"label":"ClinicalTrials.gov: trials led by LaNova Medicines","url":"https://clinicaltrials.gov/search?lead=LaNova%20Medicines%20Limited"},{"label":"Pipeline page","url":"https://www.lanovamedicines.com/en"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["lm-108"],"companies":["merck","astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05934331","nct06650566","nct06187402","nct05518045","nct07112222","nct06868199","nct07387081","nct06682780","nct05615974","nct07669415"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026. Acquisition confirmed from Sino Biopharmaceutical's HKEX filings: the 15 July 2025 discloseable transaction announcement, the 2025 annual report, and an April 2026 announcement calling LaNova a wholly owned subsidiary. The exact completion day was not found in the filings read. The LaNova website still serves and does not mention the new owner."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.lanovamedicines.com","founded":2019,"stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":950916000,"source":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042901036.pdf","note":"Sino Biopharmaceutical acquired the remaining 95.09% for a total consideration of approximately USD 950,916,000 (about RMB 6.78 billion), stated in its 2025 annual report (note 37); agreement announced 15 July 2025, and the annual report dates the full acquisition to July 2025"}],"acquiredBy":"sino-biopharm"},"route":"/companies/lanova-medicines/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct05934331","kind":"trial","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","route":"/trials/nct05934331/"},{"id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct05615974/"},{"id":"nct06682780","kind":"trial","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","route":"/trials/nct06682780/"},{"id":"nct05518045","kind":"trial","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","route":"/trials/nct05518045/"},{"id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","route":"/trials/nct06868199/"},{"id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","route":"/trials/nct07669415/"},{"id":"nct06187402","kind":"trial","name":"A Study of LM-24C5 For Advanced Solid Tumors","route":"/trials/nct06187402/"},{"id":"nct07112222","kind":"trial","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","route":"/trials/nct07112222/"},{"id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/"},{"id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","route":"/trials/nct07387081/"},{"id":"nct06650566","kind":"trial","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","route":"/trials/nct06650566/"}]}}